KR101641345B1 - 항체-약물 접합체를 이용한 병용 요법 - Google Patents

항체-약물 접합체를 이용한 병용 요법 Download PDF

Info

Publication number
KR101641345B1
KR101641345B1 KR1020107008660A KR20107008660A KR101641345B1 KR 101641345 B1 KR101641345 B1 KR 101641345B1 KR 1020107008660 A KR1020107008660 A KR 1020107008660A KR 20107008660 A KR20107008660 A KR 20107008660A KR 101641345 B1 KR101641345 B1 KR 101641345B1
Authority
KR
South Korea
Prior art keywords
antibody
alkyl
alkenyl
alkynyl
drug conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107008660A
Other languages
English (en)
Korean (ko)
Other versions
KR20100087288A (ko
Inventor
에조겔린 오프라조그루
에릭 시버스
한스 피터 거버
Original Assignee
시애틀 지네틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시애틀 지네틱스, 인크. filed Critical 시애틀 지네틱스, 인크.
Publication of KR20100087288A publication Critical patent/KR20100087288A/ko
Application granted granted Critical
Publication of KR101641345B1 publication Critical patent/KR101641345B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020107008660A 2007-10-12 2008-10-08 항체-약물 접합체를 이용한 병용 요법 Active KR101641345B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US97959407P 2007-10-12 2007-10-12
US60/979,594 2007-10-12
US2766808P 2008-02-11 2008-02-11
US61/027,668 2008-02-11
US4064108P 2008-03-28 2008-03-28
US61/040,641 2008-03-28

Publications (2)

Publication Number Publication Date
KR20100087288A KR20100087288A (ko) 2010-08-04
KR101641345B1 true KR101641345B1 (ko) 2016-07-20

Family

ID=40549535

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107008660A Active KR101641345B1 (ko) 2007-10-12 2008-10-08 항체-약물 접합체를 이용한 병용 요법

Country Status (13)

Country Link
US (2) US8263083B2 (https=)
EP (1) EP2211885B1 (https=)
JP (1) JP5485897B2 (https=)
KR (1) KR101641345B1 (https=)
CN (1) CN101969970B (https=)
AU (1) AU2008310908B2 (https=)
CA (1) CA2699090C (https=)
EA (1) EA020696B1 (https=)
IL (1) IL204851A (https=)
MX (1) MX2010003977A (https=)
NZ (1) NZ584552A (https=)
WO (1) WO2009048967A1 (https=)
ZA (1) ZA201002428B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US7750116B1 (en) * 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
DK2474557T3 (da) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
CN101969970B (zh) 2007-10-12 2014-10-15 西雅图基因公司 用抗体-药物偶联物联合治疗
SG187517A1 (en) 2008-01-31 2013-02-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
CA3159253A1 (en) 2009-01-09 2010-07-15 Seagen Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
US8758758B1 (en) * 2010-01-08 2014-06-24 Seattle Genetics, Inc. Post-relapse treatment of CD30 expressing lymphomas
AU2011213609B2 (en) * 2010-02-08 2016-11-03 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
AU2011316917B2 (en) * 2010-10-22 2016-02-25 Seagen Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
CA2848520C (en) 2011-09-29 2019-11-26 Seattle Genetics, Inc. Intact mass determination of protein conjugated agent compounds
WO2013055993A1 (en) 2011-10-14 2013-04-18 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
MY168297A (en) 2011-11-17 2018-10-23 Pfizer Cytotoxic Peptides and Antibody Drug Conjugates Thereof
EP3575794A1 (en) * 2012-02-10 2019-12-04 Seattle Genetics, Inc. Detection and treatment of cd30+ cancers
HK1214282A1 (zh) 2012-11-07 2016-07-22 辉瑞公司 抗-notch3抗体及抗体-药物缀合物
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
EP3694559A2 (en) * 2017-10-11 2020-08-19 Seattle Genetics, Inc. Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
MA50369A (fr) * 2017-10-13 2020-08-19 Seattle Genetics Inc Modulation de la réponse immunitaire à l'aide de conjugués anticorps-médicament
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
CA3094313A1 (en) * 2018-04-06 2019-10-10 Seattle Genetics, Inc. Camptothecin peptide conjugates
WO2019217455A1 (en) 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
TWI861039B (zh) 2018-12-21 2024-11-11 瑞士商赫孚孟拉羅股份公司 靶向腫瘤之促效cd28抗原結合分子
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
AU2020356955A1 (en) * 2019-10-04 2022-04-14 Seagen Inc. Camptothecin peptide conjugates
MX2022009389A (es) * 2020-01-31 2022-10-13 Seagen Inc Conjugados de farmaco-anticuerpo anti-cd30 y su uso para el tratamiento de linfoma no hodgkin.
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
CN119490595B (zh) * 2023-08-15 2025-11-18 东莞市朋志生物科技有限公司 一种抗免疫球蛋白e的抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
US20070134243A1 (en) * 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
HUE035853T2 (en) * 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
WO2007044616A2 (en) * 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
US7750116B1 (en) * 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
US8257706B2 (en) * 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
WO2008103916A2 (en) 2007-02-23 2008-08-28 The Trustees Of Columbia Univeristy In The City Of New York Compositions and methods for treating cancer or a neurotrophic disorder
CN101969970B (zh) 2007-10-12 2014-10-15 西雅图基因公司 用抗体-药物偶联物联合治疗

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bioconjug. Chem. 17(1): 114-124(2006. 1.~2.)*
Blood Rev. 21(5): 233-243(2007. 9.)*
Blood. 102(4): 1458-1465(2003. 8. 15.)

Also Published As

Publication number Publication date
US8263083B2 (en) 2012-09-11
AU2008310908B2 (en) 2014-01-09
HK1151727A1 (zh) 2012-02-10
EP2211885B1 (en) 2015-07-29
EA020696B1 (ru) 2015-01-30
IL204851A (en) 2016-08-31
WO2009048967A1 (en) 2009-04-16
EP2211885A4 (en) 2012-09-26
CN101969970B (zh) 2014-10-15
AU2008310908A1 (en) 2009-04-16
MX2010003977A (es) 2010-04-30
NZ584552A (en) 2012-07-27
CA2699090A1 (en) 2009-04-16
US20100215671A1 (en) 2010-08-26
JP5485897B2 (ja) 2014-05-07
CA2699090C (en) 2016-02-02
ZA201002428B (en) 2011-06-29
EP2211885A1 (en) 2010-08-04
KR20100087288A (ko) 2010-08-04
CN101969970A (zh) 2011-02-09
EA201070463A1 (ru) 2010-10-29
IL204851A0 (en) 2010-11-30
US20130022627A1 (en) 2013-01-24
US8470329B2 (en) 2013-06-25
JP2011500582A (ja) 2011-01-06

Similar Documents

Publication Publication Date Title
KR101641345B1 (ko) 항체-약물 접합체를 이용한 병용 요법
US20110070248A1 (en) Dr5 ligand drug conjugates
US20130280282A1 (en) Dr5 ligand drug conjugates
US20080317747A1 (en) Recombinant anti-cd30 antibodies and uses thereof
US20070258987A1 (en) Recombinant Anti-Cd30 Antibodies and Uses Thereof
US20080213289A1 (en) Recombinant anti-cd30 antibodies and uses thereof
AU2011213609A1 (en) Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
JP2006518753A (ja) 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
KR20220054321A (ko) 191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(adc)를 사용한 암의 치료
EP3890778A1 (en) Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof
CA3101943A1 (en) Therapeutic methods using antibody drug conjugates (adcs)
EP4065173A1 (en) Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
HK1151727B (en) Combination therapy with antibody-drug conjugates
EA048197B1 (ru) Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100420

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130926

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150327

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20151125

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20160420

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20160714

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20160715

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20190628

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20190628

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20200626

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20200626

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20210630

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20210630

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20220630

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20220630

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20230629

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20240624

Start annual number: 9

End annual number: 9